25Serious

Paolo Odogwu

Ask VT AI

View News Summary

Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
Restaurant Brands' Q2 profit falls, but revenue beats estimates as international growth offsets domestic challenges.
Penny stocks offer potential growth opportunities across diverse sectors, but investors must exercise caution and perform thorough analysis.

20 hours

United States Politics

Discover the latest news, candidates,  and key topics of US politics

Ask VT AI

View News Summary

Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
Restaurant Brands' Q2 profit falls, but revenue beats estimates as international growth offsets domestic challenges.
Penny stocks offer potential growth opportunities across diverse sectors, but investors must exercise caution and perform thorough analysis.

20 hours

United States Politics

Discover the latest news, candidates,  and key topics of US politics

Most Reported By
News from Paolo Odogwu